Progress of SNAC for improving oral bioavailability of macromolecular drugs

Published on Jul. 31, 2025Total Views: 74 times Total Downloads: 11 times Download Mobile

Author: SHI Qiongzhi ^1, ² XIE Xiangyang ² LI Yinke ² XU Hengjun ²  LIU Hui ^1, ²

Affiliation: 1. School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China 2. Medical Support Center, General Hospital of Central Theater Command of PLA, Wuhan 430070, China

Keywords: SNAC Permeation enhancer Macromolecular drugs Oral bioavailability Drug delivery

DOI: 10.12173/j.issn.2097-4922.202502001

Reference: SHI Qiongzhi, XIE Xiangyang, LI Yinke, XU Hengjun, LIU Hui. Progress of SNAC for improving oral bioavailability of macromolecular drugs[J]. Yaoxue QianYan Zazhi, 2025, 29(7): 1254-1260. DOI: 10.12173/j.issn.2097-4922.202502001.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), an effective drug permeation enhancer, demonstrates significant potential in improving the oral bioavailability of macromolecular drugs. This article reviews the research progress of SNAC, focusing on its physicochemical properties, safety and in vivo distribution, mechanism of action, and applications in oral macromolecular drugs.

Full-text

Please download the PDF version to read the full text: download

References

1.李艳梅, 唐祎偌, 夏旋. 索马鲁肽口服剂: 开启GLP-1受体激动剂的新时代[J]. 药品评价, 2019, 16(24): 1-3, 5. [Li YM, Tang YR, Xia X. Oral semaglutide: a herald to open the upcoming era of glucagon-like peptide-1 receptor oral agonist[J]. Drug Evaluation, 2019, 16(24): 1-3, 5.] DOI: 10.3969/j.issn.1672-2809. 2019.24.001.

2.李丹, 刘颜, 韩伟杰. 以SNAC吸收增强作用为基础的索玛鲁肽片剂研究进展[J]. 食品与药品, 2019, 21(6): 505-513. [Li D, Liu Y, Han WJ. Progress of semaglutide tablets based on SNAC absorption enhancement[J]. Food and Drug, 2019, 21(6): 505-513.] DOI: 10.3969/j.issn.1672-979X.2019.06.020.

3.Twarog C, Fattah S, Heade J, et al. Intestinal permeation enhancers for oral delivery ofmacromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10)[J]. Pharmaceutics, 2019, 11(2): 78. DOI: 10.3390/pharmaceutics11020078.

4.Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics[J]. Nature Rev Drug Dis, 2019, 18(1): 19-40. DOI: 10.1038/nrd.2018.183.

5.Renukuntla J, Vadlapudi AD, Patel A, et al. Approaches for enhancing oral bioavailability of peptides and proteins[J]. Int J Pharm, 2013, 447(1-2): 75-93. DOI: 10.1016/j.ijpharm. 2013.02.030.

6.Drucker DJ. Advances in oral peptide therapeutics[J]. Nat Rev Drug Discov, 2020, 19(4): 277-289. DOI: 10.1038/s41573-019-0053-0.

7.Spain CV, Wright JJ, Hahn RM, et al. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes[J]. Clinl Ther, 2016, 38(7): 1653-1664. DOI: 10.1016/j.clinthera.2016.05.009.

8.Bay WE, Bernadino JN, Klein GF, et al. Process for the manufacture of SNAC (salcaprozate sodium): U.S. Patent, US202107691A1[P]. 2021-03-11.

9.Mayer RJ, Breugst M, Hampel N, et al. Ambident reactivity of phenolate anions rev isited: a quantitative approach to phenolate reactivities[J]. J Org Chem, 2019, 84(14): 8837-8858. DOI: 10.1021/acs.joc.9b01485.

10.Shapira-Furman T, Bar-Hai A, Hoffman A, et al. The synthesis of SNAC phenolate s alts and the effect on oral bioavailability of semaglutide[J]. Molecules, 2024, 29(16): 3909. DOI: 10.3390/molecules29163909.

11.Gupta D, Bhatia D, Dave V, et al. Salts of therapeutic agents: chemical, physicochemical, and biological considerations[J]. Molecules, 2018, 23(7): 1719. DOI: 10.3390/molecules23071719.

12.Lyu Z, Luo QD, Tang ZY, et al. Synthesis of salcaprozate sodium and its significance in enhancing pancreatic kininogenase absorption performance[J]. Pharmacol Res Perspect, 2024, 12(2): e1186. DOI: 10.1002/prp2.1186.

13.FDA. Rybelsus (semaglutide) tablets, for oral use: FDA prescribing information[EB/OL]. (2021-03-04) [2025-01-15]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf.

14.Riley MGI, Castelli MC, Paehler EA. Subchronic oral toxicity of salcaprozate so dium (SNAC) in sprague-dawley and wistar rats[J]. Int J Toxicol, 2009, 28(4): 278-293. DOI: 10.1177/1091581809337737.

15.Rivera TM, Leone-Bay A, Paton DR, et al. Oral delivery of heparin in combinatio nwith sodium N-[8-(2-hydroxybenzoyl) amino] caprylate:pharmacological considerations[J]. Pharm Res, 1997, 14(12): 1830-1834. DOI: 10.1023/A:1012160703533.

16.McCartney F, Gleeson JP, Brayden DJ. Safety concerns over the use of intestinal p ermeation enhancers: a mini-review[J]. Tissue Barriers, 2016, 4(2): e1176822. DOI: 10.1080/21688370.2016.1176822.

17.Riley MGI, York RG. Peri-and postnatal developmental toxicity of salcaprozate so dium (SNAC) in sprague-dawley rats[J]. Inte J Toxicol, 2009, 28(4): 266-277. DOI: 10.1177/1091581809337736.

18.Kommineni N, Sainaga Jyothi VGS, Butreddy A, et al. SNAC for enhanced oral bi oavailability: an updated review[J]. Pharm Res, 2023, 40(3): 633-650. DOI: 10.1007/s11095-022-03459-9.

19.Granhall C, Bækdal TA, Breitschaft A, et al. Absence of QTc prolongation with sod ium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer co-for mulated with the GLP-1 analogue semaglutide for oral administration[J]. Diabetes Ther, 2021, 12: 2599-2610. DOI: 10.1007/s13300-021-01106-x.

20.Liu C, Kou Y, Zhang X, et al. Strategies and industrial perspectives to improve oral absorption of biological macromolecules[J]. Expert Opin Drug Deliv, 2018, 15(3): 223-233. DOI: 10.1080/17425247.2017.1395853.

21.Brayden DJ, Hill TA, Fairlie DP, et al. Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches[J]. Adv Drug Deliv Rev, 2020, 157: 2-36. DOI: 10.1016/j.addr.2020.05.007.

22.Leone-Bay A, Paton DR, Variano B, et al. Acylated non-α-amino acids as novel ag ents for the oral delivery of heparin sodium, USP[J]. J Control Rel, 1998, 50(1-3): 41-49. DOI: 10.1016/s0168-3659(97)00101-6.

23.Brayden D, Creed E, O'Connell A, et al. Heparin absorption across the intestine: effe cts of sodium N-[8-(2-hydroxybenzoyl) amino] caprylate in rat in situ intestinal instill ations and in Caco-2 monolayers[J]. Pharm Res, 1997, 14(12): 1772-1779. DOI: 10.1023/a:1012192115828.

24.Malkov D, Angelo R, Wang H, et al. Oral delivery of insulin with the eligen technology: mechanistic studies[J]. Curr Drug Deliv, 2005, 2(2): 191-197. DOI: 10.2174/1567201053586001.

25.Ding X, Rath P, Angelo R, et al. Oral absorption enhancement of cromolyn sodium through noncovalent complexation[J]. Pharm Res, 2004, 21(12): 2196-2206. DOI: 10.1007/s11095-004-7671-9.

26.Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a der ivatized glucagon-like peptide-1 receptor agonist[J]. Sci Transl Med, 2018, 10(467): eaar7047. DOI: 10.1126/scitranslmed.aar7047.

27.Mortensen JS, Bohr SSR, Harloff-Helleberg S, et al. Physical and barrier changes in gastrointestinal mucus induced by the permeation enhancer sodium 8-[(2-hydroxybe nzoyl) amino] octanoate (SNAC)[J]. J Control Release, 2022, 352: 163-178. DOI: 10.1016/j.jconrel.2022.09.034.

28.Twarog C, Liu K, O'Brien PJ, et al. A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10)[J]. Eur J Pharm Biopharm, 2020, 152: 95-107. DOI: 10.1016/j.ejpb.2020.04.023.

29.Twarog C, McCartney F, Harrison SM, et al. Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): Isolated rat intestinal mucosae and sacs[J]. Eur J Pharm Sci, 2021, 158: 105685. DOI: 10.1016/j.ejps.2020.105685.

30.Kim JC, Park EJ, Na DH. Gastrointestinal permeation enhancers for the development of oral peptide pharmaceuticals[J]. Pharmaceuticals (Basel), 2022, 15(12): 1585. DOI: 10.3390/ph15121585.

31.Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes[J]. Rev Endocrine Metabol Dis, 2022, 23(5): 979-994. DOI: 10.1007/s11154-022-09735-8.

32.Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation[J]. Front Endocrinol (Lausanne), 2021, 12: 645617. DOI: 10.3389/fendo.2021.645617.

33.Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme[J]. Diabetes Obes Metab, 2020, 22(8): 1263-1277. DOI: 10.1111/dom.14054.

34.Weng H, Hu L, Hu L, et al. The complexation of insulin with sodium N-[8-(2-h ydroxybenzoyl) amino]-caprylate for enhanced oral delivery: Effects of concentration, ratio, and pH[J]. Chin Chem Lett, 2022, 33(4): 1889-1894. DOI: 10.1016/j.cclet.2021.10.023.

35.Jain D, Panda AK, Majumdar DK. Eudragit S100 entrapped insulin microspheres for oral delivery[J]. AAPS Pharmscitech, 2005, 6(1): E100-E107. DOI: 10.1208/pt060116.

36.Pineo G, Hull R, Marder V. Oral delivery of heparin: SNAC and related formulations[J]. Best Pract Res Clin Haematol, 2004, 17(1): 153-160. DOI: 10.10 16/j.beha.2004.03.007.

37.Fattah S, Ismaiel M, Murphy B, et al. Salcaprozate sodium (SNAC) enhances permea bility of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers[J]. Eur J Pharm Sci, 2020, 154: 105509. DOI: 10.1016/j.ejps.2020.105509.

38.Niu Z, La Zara D, Blaabjerg L, et al. Combining SNAC and C10 in oral tablet formulations for gastric peptide delivery: a preclinical and clinical study[J]. J Control Release, 2025, 378: 92-102. DOI: 10.1016/j.jconrel.2024.11.078.